Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 8/20 | 0.59 |
| ▸ | ADRB1 | P08588 | 6/20 | 0.59 |
| ▸ | TSHR | P16473 | 2/20 | 0.59 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.59 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.59 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.59 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.59 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.58 |
| ▸ | ADRB3 | P13945 | 5/20 | 0.58 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.56 |
| ▸ | ADRA1D | P25100 | 3/20 | 0.50 |
| ▸ | ADRA1A | P35348 | 3/20 | 0.50 |
| ▸ | ADRA1B | P35368 | 3/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | CASP7 | P55210 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | CA12 | O43570 | 1/20 | 0.49 |
| ▸ | CA1 | P00915 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14134261 | 0.86 | ADRB2 (0.49) | ADRB2ADRB1TSHRHIF1ACYP1A2 | |
| SCHEMBL14134262 | 0.86 | ADRB2 (0.49) | ADRB2ADRB1TSHRHIF1ACYP1A2 | |
| SCHEMBL8067713 | 0.86 | ADRB2 (0.62) | ADRB2ADRB1TSHRHIF1ACYP1A2 | |
| Hydrochloric Acid SCHEMBL11596685 | 0.84 | TDP1 (0.61) | ADRB2ADRB1TSHRHIF1ACYP1A2 | |
| SCHEMBL13589394 | 0.80 | CA12 (0.54) | ADRB2ADRB1TSHRNFKB1ADRB3 | |
| SCHEMBL9701421 | 0.80 | NFKB1 (0.59) | ADRB2ADRB1TSHRHIF1ANFKB1 | |
| SCHEMBL7154449 | 0.80 | NFKB1 (0.59) | ADRB2ADRB1TSHRHIF1ANFKB1 | |
| Colterol SCHEMBL3207818 | 0.79 | ADRB2 (0.72) | ADRB2ADRB1TSHRHIF1ACYP1A2 | |
| Colterol SCHEMBL3220142 | 0.79 | ADRB2 (0.72) | ADRB2ADRB1TSHRHIF1ACYP1A2 | |
| Colterol SCHEMBL249585 | 0.79 | ADRB2 (0.72) | ADRB2ADRB1TSHRHIF1ACYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0763010-B1 | ENANTIOSELECTIVE PREPARATION OF OPTICALLY PURE ALBUTEROL | SEPRACOR INC (US) | 2000-08-30 | — | — | EP | claimed |
| EP-0763010-A4 | ENANTIOSELECTIVE PREPARATION OF OPTICALLY PURE ALBUTEROL | SEPRACOR INC (US) | 1997-07-16 | — | — | EP | claimed |
| EP-0763010-A1 | ENANTIOSELECTIVE PREPARATION OF OPTICALLY PURE ALBUTEROL | SEPRACOR, INC. (US) | 1997-03-19 | — | — | EP | claimed |
| WO-1995032178-A1 | ENANTIOSELECTIVE PREPARATION OF OPTICALLY PURE ALBUTEROL | SEPRACOR, INC. (US) | 1995-11-30 | — | — | WO | claimed |
| US-5399765-A | Salt formation | SEPRACOR, INC. (US) | 1995-03-21 | — | — | US | claimed |
| EP-2099740-B1 | A PROCESS FOR THE PREPARATION OF OPTICALLY PURE R (-) SALBUTAMOL AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS | AARTI HEALTHCARE LTD (IN) | 2013-08-14 | — | — | EP | disclosed |
| US-8063251-B2 | Process for the preparation of optically pure R (−) salbutamol and its pharmaceutically acceptable salts | AARTI HEALTHCARE LIMITED (IN) | 2011-11-22 | — | — | US | disclosed |
| US-20100204516-A1 | PROCESS FOR THE PREPARATION OF OPTICALLY PURE R (-) SALBUTAMOL AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS | AARTI HEALTHCARE LIMITED (IN) | 2010-08-12 | — | — | US | disclosed |
| EP-2099740-A1 | A PROCESS FOR THE PREPARATION OF OPTICALLY PURE R (-) SALBUTAMOL AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS | Aarti Healthcare Limited (IN) | 2009-09-16 | — | — | EP | disclosed |
| US-7482489-B2 | Enantiomerically pure (R)-albuterol dibenzoyltartrate and protected analogs thereof | TEVA PHARMACEUTICAL FINE CHEMICALS S.R.L. (IT) | 2009-01-27 | — | — | US | disclosed |
| US-7482489-B2 | Enantiomerically pure (R)-albuterol dibenzoyltartrate and protected analogs thereof | TEVA PHARMACEUTICAL FINE CHEMICALS S.R.L. (IT) | 2009-01-27 | — | — | US | disclosed |
| US-7482489-B2 | Enantiomerically pure (R)-albuterol dibenzoyltartrate and protected analogs thereof | TEVA PHARMACEUTICAL FINE CHEMICALS S.R.L. (IT) | 2009-01-27 | — | — | US | disclosed |
| EP-1747189-A1 | PREPARATION OF LEVALBUTEROL HYDROCHLORIDE | Teva Pharmaceutical Fine Chemicals S.R.L. (IT) | 2007-01-31 | — | — | EP | disclosed |
| WO-2005113481-A1 | PREPARATION OF LEVALBUTEROL HYDROCHLORIDE | TEVA PHARMACEUTICAL FINE CHEMICALS S.R.L. (IT) | 2005-12-01 | — | — | WO | disclosed |
| US-20050261368-A1 | Preparation of levalbuterol hydrochloride | TEVA PHARMACEUTICAL FINE CHEMICALS S.R.I. (IT) | 2005-11-24 | — | — | US | disclosed |
| EP-0763010-B1 | ENANTIOSELECTIVE PREPARATION OF OPTICALLY PURE ALBUTEROL | SEPRACOR INC (US) | 2000-08-30 | — | — | EP | disclosed |
| EP-0763010-A4 | ENANTIOSELECTIVE PREPARATION OF OPTICALLY PURE ALBUTEROL | SEPRACOR INC (US) | 1997-07-16 | — | — | EP | disclosed |
| EP-0763010-A1 | ENANTIOSELECTIVE PREPARATION OF OPTICALLY PURE ALBUTEROL | SEPRACOR, INC. (US) | 1997-03-19 | — | — | EP | disclosed |
| WO-1995032178-A1 | ENANTIOSELECTIVE PREPARATION OF OPTICALLY PURE ALBUTEROL | SEPRACOR, INC. (US) | 1995-11-30 | — | — | WO | disclosed |
| US-5399765-A | Salt formation | SEPRACOR, INC. (US) | 1995-03-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100204516-A1 | PROCESS FOR THE PREPARATION OF OPTICALLY PURE R (-) SALBUTAMOL AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS | FFAR4, ADRB1, NR1H4 | ADRB2 12/4885ADRB1 2/4885TSHR 1107/4885 |
| US-20050261368-A1 | Preparation of levalbuterol hydrochloride | LDHB, DLST, DAGLB | ADRB2 144/4885ADRB1 88/4885TSHR 2097/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.